MGN1601: Additional Phase I/II data

Data from 10 evaluable patients who completed 12 weeks of treatment in the open-label, German Phase I/II ASET trial showed that MGN1601 led to an average survival time of >10 months with 1 partial response and 2 cases of stable disease. Median progression-free survival (PFS) was 12 weeks and median overall survival (OS) has not yet been reached. The trial enrolled 19 patients with advanced RCC who failed previous therapies to receive 3 weekly doses of intradermal MGN1601 followed by 5 biweekly doses. Data were presented at the American Association for Cancer Research meeting in Chicago. ...